LeMaitre Vascular, Inc. (NASDAQ:LMAT) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On July27, 2017, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its financial and operational results for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Report.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
On July25, 2017, the Company’s Board of Directors authorized the repurchase of up to $7.5million of the Company’s outstanding common stock from time to time on the open market or in privately negotiated transactions. The timing and number of any shares repurchased will be determined by Company management, based on their evaluation of market conditions and other factors. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The repurchase program may be suspended or discontinued at any time and will conclude no later than July25, 2018, unless extended by the Company’s Board of Directors. The repurchase program will be funded using the Company’s available cash and cash equivalents.
| Item 2.02. | Financial Statements and Exhibits. |
The following exhibits are furnished or filed as part of this Report, as applicable:
|
Exhibit No. |
Description |
| 99.1 | Press release issued by LeMaitre Vascular, Inc. on July27, 2017. |
(s)
LEMAITRE VASCULAR INC ExhibitEX-99.1 2 d421260dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q2 2017 Record Sales $25.8 mm (+15%),…To view the full exhibit click here
About LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
